Industrial breakouts and definitive biotech M&A flows are setting the pace today, while retail gappers test key institutional support zones ahead of next week's macro gauntlet.
TG Therapeutics reported Q2 2026 revenue of $240M, easily beating estimates as U.S. BRIUMVI sales jumped 64% Y/Y to $227.7M. Management raised full-year revenue guidance to $950M with a $1B exit run rate, triggering a high-volume breakout from a multi-week upper-$40s base to close at $55.42 on Saturday.
Why it matters
This is a textbook episodic pivot combining top-line outperformance with aggressive forward guidance. Heavy volume confirmation above the prior $52 pivot level indicates institutional accumulation. For your trading desk, track continuation above $54 while keeping risk defined against the $50 breakout pivot.
Building on the 8% post-market gap we noted earlier, Ross Stores closed Friday's regular session at $239.04 on heavy volume of nearly 7 million shares. The continuation run is anchored by its strong Q2 beat—EPS of $2.66 crushed consensus by $0.81, aided by a tariff refund—and management's raised full-year EPS outlook of $8.61–$8.77 on 10% comp growth.
Why it matters
ROST represents one of the week's cleanest institutional earnings gappers, holding post-market gains in the $241–$249 zone. The combination of traffic-driven top-line growth and operating margin expansion provides strong momentum setup parameters. Watch for opening drive continuation or a VWAP hold above $238.
Freeport-McMoRan surged 7.64% on Saturday to close at $76.66, clearing mid-$70s technical resistance on heavy relative volume. The breakout builds on Q2 adjusted EPS of $0.74 (vs. $0.62 consensus), $7.03B in revenue, and $2.05B in Q2 free cash flow driven by tightening physical copper markets.
Why it matters
FCX is acting as the primary liquid proxy for physical copper demand tied to data center power expansion and grid buildout. The clear volume-confirmed breakout past $75 sets up a continuation play for momentum desks. Second-order sympathy moves in Southern Copper (SCCO) confirm sector-wide capital inflows.
Strategy Inc. shares surged 27% over five sessions to touch $120 as Bitcoin approached $79,000, bringing MSTR's 849,447 BTC stack to $1.15B in unrealized profit. SEC filings indicate MSTR raised $333.7M via equity sales without making fresh crypto purchases for the seventh consecutive week.
Why it matters
MSTR continues to function as an amplified high-beta equity vehicle for Bitcoin price swings. The push past its multi-month consolidation base brings the stock directly against its $122 100-day EMA resistance. Watch for a high-volume breakout or exhaustion reversal if BTC rejects $80,000.
Arbutus Biopharma announced a modified Dutch auction repurchase of up to $230M in common stock priced between $5.00 and $5.75 per share on Saturday. The buyback is fully funded by its $950M global patent settlement with Moderna, pushing ABUS shares up 10.86% on heavy volume.
Why it matters
The $5.00–$5.75 tender range establishes a hard valuation floor and asymmetric downside risk for swing traders. Combined with ongoing LNP patent litigation against Pfizer/BioNTech, the settlement windfall converts ABUS into an event-driven catalyst play. Immediate technical support rests firm at the $4.90–$5.10 clustering zone.
Virtu Financial traded up 12% on Saturday following reports that the firm is exploring a $3.5B–$4.0B sale of its agency brokerage and technology division. Piper Sandler maintained an Outperform rating and $70 target, noting that redeploying capital into core market-making could yield 40% EPS accretion by 2027.
Why it matters
A multi-billion dollar divestiture would fundamentally re-rate VIRT's balance sheet while providing massive liquidity for accretive buybacks or core trading capital. Takeover chatter reported by Betaville adds additional M&A optionality. Order flow shows aggressive dip-buying with technical support well-anchored in the $61–$62 zone.
Boeing shares tumbled 7.5% for the week to $214.20 after approximately 17,000 unionized engineers and technical workers rejected a four-year contract offer and voted for strike authorization. While work stoppages are blocked until the contract expires October 6, the vote threatens key 737-10 and 777-9 certification timelines.
Why it matters
Labor friction among core engineering staff directly jeopardizes Boeing's delivery execution and free cash flow targets despite a $715B backlog. The $13.8B market cap drop reflects immediate risk premium pricing ahead of the October 7 deadline. Look for short-side setups or put flow acceleration if support near $210 breaks.
Ford Motor finally cleared its $13.80–$15.00 consolidation band on Friday, surging 3.47%. The breakout confirms the technical follow-through we've been watching for since July's Q2 beat-and-raise (which lifted 2026 adjusted EBIT guidance to the $10B–$11B range) and the accompanying Jefferies upgrade, bolstered by a projected $6B–$7B in free cash flow.
Why it matters
With the fundamental pivot from July now translating into technical momentum, the stock provides a strong multi-week swing candidate as core cash generation outweighs EV segment drag. Volume expansion on this breakout creates a defined risk-reward entry, with invalidation resting on a close back inside the $13.80 range.
Royal Bank of Canada raised its price target on Target Corporation to $178 from $166 with an Outperform rating. The upgrade follows Q2 EPS of $4.11 vs $2.35 consensus on $26.54B in revenue, which allowed management to raise full-year 2026 guidance to $9.90–$10.90 per share.
Why it matters
TGT is drawing sustained sell-side target hikes following its massive quarterly beat, though desks remain split on the $994M tariff refund benefit. For swing traders, the stock's post-earnings consolidation pattern offers clear parameters for continuation trades toward the $178 consensus target.
O-I Glass shares jumped 11.91% to $7.18 on Saturday after Citigroup upgraded the ticker from Neutral to Buy, raising its price target to $9.00 and placing it on a 90-day upside catalyst watch. The upgrade follows a 57% YTD sell-off and Q2 furnace impairment charges, capitalizing on $1.67B in core revenue.
Why it matters
This is a high-reward mean-reversion setup in a washed-out industrial leader trading at ~0.15x sales. The tier-1 upgrade and catalyst watch tag provide the spark for short covering off deeply depressed levels. Use $6.40 as the hard technical invalidation floor for swing long positioning.
Quantum computing names including Infleqtion, Rigetti (RGTI), IonQ (IONQ), and D-Wave (QBTS) jumped 7% to 10% in a coordinated single-session rally on Friday. The move followed U.S. Department of Commerce letters of intent outlining up to $100M in proposed federal contract funding for Infleqtion and Rigetti.
Why it matters
Federal funding commitments served as a group-wide catalyst for a synchronized thematic rotation off depressed technical bases. For intraday and momentum swing traders, watch for second-day continuation flow across pure-play quantum tickers. Keep position duration tight as underlying cash burn remains a structural drag.
The United States invoked Section 338 of the Tariff Act to impose 50% tariffs on $20B of Canadian imports on Saturday following a breakdown in trade talks. Canadian Prime Minister Mark Carney announced dollar-for-dollar retaliatory tariffs targeting steel, agriculture, and equipment effective September 8.
Why it matters
The sudden trade friction introduces severe supply chain disruption for cross-border auto, steel, and industrial names ahead of September 8. Volatility across Canadian dollar crosses (USD/CAD) and industrial importers creates actionable short-term macro setups as the USMCA framework faces structural risk.
Copper Proxies Confirm Broadening Industrial Expansion Freeport-McMoRan and Southern Copper are breaking out of multi-week bases on expanding volume, validating physical commodity demand tied to data center grid modernization.
Capital Injection and Cash tender Offers Establish Biotech Floor Pricing Settlement Windfalls and Dutch auction buybacks (such as Arbutus) are converting cash-strapped biotech names into balance-sheet plays with defined technical downside risk.
Off-Price Retail Operating Leverage Squeezes Post-Earnings Shorts Ross Stores and Target are demonstrating strong post-earnings continuation as consumer value shifts and tariff refunds drive significant EPS beats.
Tier-1 Sell-Side Revisions Accelerate High-Beta Upward Drift Aggressive price target raises on Ford, O-I Glass, and Box are providing the necessary volume confirmation for swing continuations ahead of broad macro catalysts.
Pre-Earnings Positioning Intensifies Across Mega-Cap Semiconductor Interconnects Options desks are pricing double-digit moves for Marvell and Nvidia as physical hardware constraints and memory cost increases shift forward revenue targets.